This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ip, C. Articles by Ganther, H. E. Search for Related Content PubMed PubMed Citation Articles by Ip, C. Articles by Ganther, H. E.

Selenium Modulation of Cell Proliferation and Cell Cycle Biomarkers in Normal and Premalignant Cells of the Rat Mammary Gland¹

Department of Experimental Pathology, Roswell Park Cancer Institute, Buffalo, New York 14263 [C. I.]; Center for Nutrition in the Prevention of Disease, AMC Cancer Research Center, Denver, Colorado 80214 [H. J. T.]; and Department of Nutritional Sciences, University of Wisconsin, Madison, Wisconsin 53706 [H. E. G.]

The present study was designed to assess the effect of Se-methylselenocysteine or triphenylselenonium chloride treatment on cell proliferation [bromodeoxyuridine (BrdUrd) labeling] and cell cycle biomarkers [proliferating cell nuclear antigen (PCNA), cyclin D₁, and p27/Kip 1] in the intact mammary gland of rats. Immunohistochemical assays of the above end points were carried out in different morphological structures: (a) terminal end bud cells and alveolar cells of a maturing mammary gland undergoing active differentiation; and (b) premalignant mammary intraductal proliferations (IDPs) identified at 6 weeks after carcinogen dosing. Neither compound was found to affect BrdUrd labeling or the expression of cell cycle biomarkers in the normal terminal-end bud cells and alveolar cells. Se-methylselenocysteine reduced the total number of IDP lesions by 60%. Interestingly, this was not accompanied by decreases in BrdUrd labeling or the proportion of IDP cells expressing PCNA and cyclin D₁. An enhancement in the fraction of p27/Kip 1-positive IDP cells, however, was detected as a result of Se-methylselenocysteine treatment. Although triphenylselenonium chloride did not reduce the total number of IDPs, there were more of the smaller-sized lesions and fewer of the larger-sized lesions compared with those found in the control group. Triphenylselenonium chloride also significantly decreased the proportion of IDP cells incorporating the BrdUrd label or expressing PCNA and cyclin D₁. The above findings suggest that early transformed cells are sensitive to selenium intervention, whereas normal proliferating cells are not. It is possible that Se-methylselenocysteine blocks carcinogenesis by a pathway that may not involve cell growth inhibition as a primary response; in contrast, triphenylselenonium chloride is likely to act by a cytostatic mechanism. The data also imply that selenium efficacy testing in intervention trials is possible with the use of biomarkers, provided that the appropriate biomarkers are matched with the selenium compound of interest and that the pathological characteristics of the cell population to be evaluated are taken into consideration.

This article has been cited by other articles:

				D. J. Waters, S. Shen, L. T. Glickman, D. M. Cooley, D. G. Bostwick, J. Qian, G. F. Combs Jr, and J. S. Morris Prostate cancer risk and DNA damage: translational significance of selenium supplementation in a canine model Carcinogenesis, July 1, 2005; 26(7): 1256 - 1262. [Abstract] [Full Text] [PDF]

				A. L. Lock, B. A. Corl, D. M. Barbano, D. E. Bauman, and C. Ip The Anticarcinogenic Effect of trans-11 18:1 Is Dependent on Its Conversion to cis-9, trans-11 CLA by {Delta}9-Desaturase in Rats J. Nutr., October 1, 2004; 134(10): 2698 - 2704. [Abstract] [Full Text] [PDF]

				N. V. Gopee, V. J. Johnson, and R. P. Sharma Sodium Selenite-Induced Apoptosis in Murine B-Lymphoma Cells Is Associated with Inhibition of Protein Kinase C-{delta}, Nuclear Factor {kappa}B, and Inhibitor of Apoptosis Protein Toxicol. Sci., April 1, 2004; 78(2): 204 - 214. [Abstract] [Full Text] [PDF]

				S. Cao, F. A. Durrani, and Y. M. Rustum Selective Modulation of the Therapeutic Efficacy of Anticancer Drugs by Selenium Containing Compounds against Human Tumor Xenografts Clin. Cancer Res., April 1, 2004; 10(7): 2561 - 2569. [Abstract] [Full Text] [PDF]

				H. Zhao, M. L. Whitfield, T. Xu, D. Botstein, and J. D. Brooks Diverse Effects of Methylseleninic Acid on the Transcriptional Program of Human Prostate Cancer Cells Mol. Biol. Cell, February 1, 2004; 15(2): 506 - 519. [Abstract] [Full Text] [PDF]

				H. Zeng and C. D. Davis Down-Regulation of Proliferating Cell Nuclear Antigen Gene Expression Occurs during Cell Cycle Arrest Induced by Human Fecal Water in Colonic HT-29 Cells J. Nutr., August 1, 2003; 133(8): 2682 - 2687. [Abstract] [Full Text] [PDF]

				R. E. Rudolph, T. L. Vaughan, A. R. Kristal, P. L. Blount, D. S. Levine, P. C. Galipeau, L. J. Prevo, C. A. Sanchez, P. S. Rabinovitch, and B. J. Reid Serum Selenium Levels in Relation to Markers of Neoplastic Progression Among Persons With Barrett's Esophagus J Natl Cancer Inst, May 21, 2003; 95(10): 750 - 757. [Abstract] [Full Text] [PDF]

				D. J. Waters, S. Shen, D. M. Cooley, D. G. Bostwick, J. Qian, G. F. Combs Jr., L. T. Glickman, C. Oteham, D. Schlittler, and J. S. Morris Effects of Dietary Selenium Supplementation on DNA Damage and Apoptosis in Canine Prostate J Natl Cancer Inst, February 5, 2003; 95(3): 237 - 241. [Abstract] [Full Text] [PDF]

				H. Zeng Selenite and Selenomethionine Promote HL-60 Cell Cycle Progression J. Nutr., April 1, 2002; 132(4): 674 - 679. [Abstract] [Full Text] [PDF]

				Y. Dong, H. E. Ganther, C. Stewart, and C. Ip Identification of Molecular Targets Associated with Selenium-induced Growth Inhibition in Human Breast Cells Using cDNA Microarrays Cancer Res., February 1, 2002; 62(3): 708 - 714. [Abstract] [Full Text] [PDF]

				Z. Zhu, W. Jiang, H. E. Ganther, and H. J. Thompson Mechanisms of Cell Cycle Arrest by Methylseleninic Acid Cancer Res., January 1, 2002; 62(1): 156 - 164. [Abstract] [Full Text] [PDF]

				G. E. Goodman, S. Schaffer, D. D. Bankson, M. P. Hughes, and G. S. Omenn Predictors of Serum Selenium in Cigarette Smokers and the Lack of Association with Lung and Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., October 1, 2001; 10(10): 1069 - 1076. [Abstract] [Full Text] [PDF]

				J. W. Crott, S. T. Mashiyama, B. N. Ames, and M. F. Fenech Methylenetetrahydrofolate reductase C677T polymorphism does not alter folic acid deficiency-induced uracil incorporation into primary human lymphocyte DNA in vitro Carcinogenesis, July 1, 2001; 22(7): 1019 - 1025. [Abstract] [Full Text] [PDF]

				T. Kim, U. Jung, D.-Y. Cho, and A.-S. Chung Se-Methylselenocysteine induces apoptosis through caspase activation in HL-60 cells Carcinogenesis, April 1, 2001; 22(4): 559 - 565. [Abstract] [Full Text] [PDF]

				Y. Dong, D. Lisk, E. Block, and C. Ip Characterization of the Biological Activity of {{gamma}}-Glutamyl-Se- methylselenocysteine: A Novel, Naturally Occurring Anticancer Agent from Garlic Cancer Res., April 1, 2001; 61(7): 2923 - 2928. [Abstract] [Full Text]

				C. Jiang, Z. Wang, H. Ganther, and J. Lu Caspases as Key Executors of Methyl Selenium-induced Apoptosis (Anoikis) of DU-145 Prostate Cancer Cells Cancer Res., April 1, 2001; 61(7): 3062 - 3070. [Abstract] [Full Text]

				H. E. Ganther and C. Ip Thioredoxin Reductase Activity in Rat Liver Is Not Affected by Supranutritional Levels of Monomethylated Selenium In Vivo and Is Inhibited Only by High Levels of Selenium In Vitro J. Nutr., February 1, 2001; 131(2): 301 - 304. [Abstract] [Full Text]

				D. G. Menter, A. L. Sabichi, and S. M. Lippman Selenium Effects on Prostate Cell Growth Cancer Epidemiol. Biomarkers Prev., November 1, 2000; 9(11): 1171 - 1182. [Abstract] [Full Text]

				C. Ip, M. M. Ip, T. Loftus, S. Shoemaker, and W. Shea-Eaton Induction of Apoptosis by Conjugated Linoleic Acid in Cultured Mammary Tumor Cells and Premalignant Lesions of the Rat Mammary Gland Cancer Epidemiol. Biomarkers Prev., July 1, 2000; 9(7): 689 - 696. [Abstract] [Full Text]